BioCryst Pharmaceuticals Inc (BCRX) shareholders
Close on Nov 18, 2026Market cap $1.87BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 17,483,490 | 8.40% | 13G (passive) amendment | Mar 31, 2025 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (6.20%), Peter Kolchinsky (6.20%) and 1 more | 15,827,186 | 6.20% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (7.30%), Rajeev Shah (7.30%) and 1 more | 15,302,186 | 7.30% | 13G (passive) | Nov 4, 2025 |
| James E. Flynn Joint filing with Deerfield Mgmt, L.P. (6.81%), Deerfield Management Company, L.P. (6.81%) and 1 more | 14,341,000 | 6.81% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Capital Management | 12,961,172 | 5.16% | 13G (passive) | Mar 31, 2026 |
| Deerfield Mgmt, L.P. Joint filing with Deerfield Management Company, L.P. (5.80%), Deerfield Partners, L.P. (5.80%) and 1 more | 12,169,000 | 5.80% | 13G (passive) | Sep 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BCRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23,893,036 | 9.35% | $238.93M | +1,242,048 | 0.00% |
| Ra Capital Management, L.P. | 15,827,186 | 6.19% | $158.27M | – | 1.38% |
| State Street Corp | 15,191,098 | 5.94% | $151.91M | +2,982,738 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 15,096,403 | 5.91% | $150.96M | +58,403 | 1.57% |
| Vanguard Capital Management LLC | 11,364,236 | 4.45% | $113.64M | +228,474 | 0.00% |
| Vanguard Portfolio Management LLC | 11,139,158 | 4.36% | $111.39M | −105,467 | 0.01% |
| TCG Crossover Management, LLC | 11,020,968 | 4.31% | $110.21M | – | 2.65% |
| Perceptive Advisors LLC | 10,308,888 | 4.03% | $103.09M | +2,874,855 | 1.55% |
| Jupiter Topco LLC | 9,540,764 | 3.73% | $95.27M | New | 0.04% |
| Vestal Point Capital, LP | 8,300,000 | 3.25% | $83.00M | +1,275,000 | 1.94% |
| Two Sigma Investments, LP | 6,775,349 | 2.65% | $67.75M | +382,721 | 0.05% |
| Geode Capital Management, LLC | 6,248,046 | 2.45% | $62.49M | +465,270 | 0.00% |
| abrdn plc | 5,310,871 | 2.08% | $53.11M | +270,201 | 0.07% |
| UBS Group AG | 5,078,280 | 1.99% | $50.78M | +134,286 | 0.01% |
| Bank Of America Corp /De/ | 4,801,284 | 1.88% | $48.01M | −290,481 | 0.00% |
| Goldman Sachs Group Inc | 4,481,874 | 1.75% | $44.82M | +2,134,431 | 0.00% |
| Frazier Life Sciences Management, L.P. | 4,009,240 | 1.57% | $40.09M | – | 0.87% |
| Nuveen, LLC | 4,007,237 | 1.57% | $40.07M | +187,974 | 0.01% |
| Nantahala Capital Management, LLC | 3,802,320 | 1.49% | $38.02M | +1,814,923 | 0.63% |
| Millennium Management LLC | 3,394,729 | 1.33% | $33.95M | +3,207,008 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 318 | 264M | 100.0% | 56 / 134 | 86 / 37 | 48M | 25M |
| Q1 2026 | 302 | 249M | 97.5% | 74 / 114 | 78 / 41 | 91M | 32M |
| Q4 2025 | 273 | 213M | 83.2% | 49 / 91 | 101 / 57 | 59M | 41M |
| Q3 2025 | 286 | 195M | 76.4% | 37 / 96 | 105 / 41 | 27M | 29M |
| Q2 2025 | 294 | 197M | 77.3% | 52 / 113 | 85 / 30 | 50M | 28M |
| Q1 2025 | 274 | 175M | 68.6% | 42 / 109 | 71 / 24 | 25M | 14M |
| Q4 2024 | 258 | 168M | 65.7% | 34 / 79 | 91 / 32 | 11M | 17M |
| Q3 2024 | 257 | 174M | 68.1% | 52 / 79 | 75 / 34 | 34M | 16M |
| Q2 2024 | 242 | 175M | 68.6% | 43 / 84 | 69 / 37 | 33M | 44M |
| Q1 2024 | 238 | 186M | 73.0% | 31 / 84 | 71 / 27 | 24M | 18M |
| Q4 2023 | 235 | 181M | 70.7% | 32 / 84 | 75 / 26 | 34M | 29M |
| Q3 2023 | 233 | 176M | 68.8% | 21 / 102 | 58 / 22 | 21M | 14M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
223 funds held BCRX in Q2 2026, 67% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BCRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 9,581,829 | 3.75% | $95.82M | 0.89% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 8,067,362 | 3.16% | $80.67M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,047,716 | 2.37% | $60.48M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,911,465 | 1.14% | $29.11M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,838,097 | 1.11% | $28.38M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,538,144 | 0.99% | $22.79M | 0.07% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 2,255,073 | 0.88% | $22.55M | 0.19% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 2,149,216 | 0.84% | $21.49M | 0.14% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,671,689 | 0.65% | $16.72M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,528,937 | 0.60% | $15.29M | 0.17% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 1,386,232 | 0.54% | $13.86M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,341,254 | 0.52% | $12.04M | 0.05% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 1,247,457 | 0.49% | $11.11M | 0.03% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,162,856 | 0.46% | $10.36M | 0.06% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,154,262 | 0.45% | $10.28M | 0.05% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alane P. Barnes | Chief Legal Officer | 463,203 | 0.18% | May 15, 2026 |
| Sandeep Menon | Chief R&D Officer | 205,150 | 0.08% | Apr 7, 2026 |
| Ronald Dullinger | Chief Commercial Officer | 258,372 | 0.10% | Jan 9, 2026 |
| Charles K. Gayer | President and CCO | 902,583 | 0.35% | Dec 23, 2025 |
| Babar Ghias | Chief Financial Officer | 268,700 | 0.11% | Dec 19, 2025 |
| Helen M. Thackray | Chief R&D Officer | 377,318 | 0.15% | Apr 2, 2025 |
| Anthony Doyle | Chief Financial Officer | 377,867 | 0.15% | Dec 23, 2024 |
| Amy E. McKee | Director | 47,821 | 0.02% | Sep 2, 2026 |
| Jon P. Stonehouse | Director | 1,420,419 | 0.56% | Sep 2, 2026 |
| Jill C. Milne | Director | 33,226 | 0.01% | Sep 2, 2026 |
| Vincent Milano | Director | 109,642 | 0.04% | Sep 2, 2026 |
| Steven Frank | Director | 36,747 | 0.01% | Sep 2, 2026 |
| Machelle Sanders | Director | 45,936 | 0.02% | Jun 15, 2026 |
| Alan G. Levin | Director | 79,565 | 0.03% | Jun 15, 2026 |
| Steven K. Galson | Director | 86,165 | 0.03% | Jun 15, 2026 |
| Theresa Heggie | Director | 80,646 | 0.03% | Jun 15, 2026 |
| Nancy J. Hutson | Director | 99,138 | 0.04% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jill C. Milne Director | Aug 31, 2026 | Award | +1,288 | $9.70 | $12.49K | 33,226 |
| Jon P. Stonehouse Director | Aug 31, 2026 | Award | +644 | $9.70 | $6.25K | 1,340,419 |
| Amy E. McKee Director | Aug 31, 2026 | Award | +644 | $9.70 | $6.25K | 47,821 |
| Steven Frank Director | Aug 31, 2026 | Award | +1,288 | $9.70 | $12.49K | 36,747 |
| Vincent Milano Director | Aug 31, 2026 | Award | +1,159 | $9.70 | $11.24K | 109,642 |
| Steven Frank Director | Jun 11, 2026 | Award | +15,294 | – | – | 35,459 |
| Jill C. Milne Director | Jun 11, 2026 | Award | +15,294 | – | – | 31,938 |
| Steven K. Galson Director | Jun 11, 2026 | Award | +15,294 | – | – | 27,794 |
| Theresa Heggie Director | Jun 11, 2026 | Award | +15,294 | – | – | 80,646 |
| Machelle Sanders Director | Jun 11, 2026 | Award | +15,294 | – | – | 45,936 |
| Vincent Milano Director | Jun 11, 2026 | Award | +15,294 | – | – | 108,483 |
| Jon P. Stonehouse Director | Jun 11, 2026 | Award | +15,294 | – | – | 1,339,775 |
| Alan G. Levin Director | Jun 11, 2026 | Award | +15,294 | – | – | 79,565 |
| Amy E. McKee Director | Jun 11, 2026 | Award | +15,294 | – | – | 47,177 |
| Jill C. Milne Director | May 29, 2026 | Award | +1,262 | $8.91 | $11.24K | 16,644 |
| Vincent Milano Director | May 29, 2026 | Award | +1,122 | $8.91 | $10.00K | 93,189 |
| Jon P. Stonehouse Director | May 29, 2026 | Award | +631 | $8.91 | $5.62K | 1,324,481 |
| Steven Frank Director | May 29, 2026 | Award | +1,262 | $8.91 | $11.24K | 20,165 |
| Amy E. McKee Director | May 29, 2026 | Award | +631 | $8.91 | $5.62K | 31,883 |
| Amy E. McKee Director | May 18, 2026 | Sale | −11,180 | $8.97 | $100.28K | 31,252 |
| Alane P. Barnes Chief Legal Officer | May 13, 2026 | Option exercise | +62,500 | $5.04 | $315.00K | 463,203 |
| Alane P. Barnes Chief Legal Officer | May 13, 2026 | Sale(10b5-1 plan) | −62,500 | $9.54 | $596.25K | 400,703 |
| Sandeep Menon Chief R&D Officer | Apr 6, 2026 | Award | +205,150 | – | – | 205,150 |
| Theresa Heggie Director | Mar 20, 2026 | Sale | −49,933 | $10.11 | $504.82K | 65,352 |
| Theresa Heggie Director | Mar 20, 2026 | Option exercise | +49,933 | $6.30 | $314.58K | 115,285 |
| Alane P. Barnes Chief Legal Officer | Mar 16, 2026 | Option exercise | +150,000 | $5.51 | $826.50K | 550,703 |
| Alane P. Barnes Chief Legal Officer | Mar 16, 2026 | Sale(10b5-1 plan) | −150,000 | $9.15 | $1.37M | 400,703 |
| Jon P. Stonehouse Director | Mar 2, 2026 | Option exercise | +305,995 | $3.22 | $985.30K | 1,629,845 |
| Jon P. Stonehouse Director | Mar 2, 2026 | Returned to company | −305,995 | $8.64 | $2.64M | 1,323,850 |
| Steven Frank Director | Feb 27, 2026 | Award | +1,285 | $8.75 | $11.24K | 18,903 |
| Amy E. McKee Director | Feb 27, 2026 | Award | +642 | $8.75 | $5.62K | 42,432 |
| Jon P. Stonehouse Director | Feb 27, 2026 | Award | +421 | $8.75 | $3.68K | 1,323,850 |
| Vincent Milano Director | Feb 27, 2026 | Award | +848 | $8.75 | $7.42K | 92,067 |
| Jill C. Milne Director | Feb 27, 2026 | Award | +528 | $8.75 | $4.62K | 15,382 |
| Jill C. Milne Director | Jan 23, 2026 | Award | +12,272 | – | – | 14,854 |
| Jill C. Milne Director | Jan 23, 2026 | Award | +2,582 | – | – | 2,582 |
| Alane P. Barnes Chief Legal Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −21,773 | $7.65 | $166.56K | 398,751 |
| Charles K. Gayer President and CCO | Dec 22, 2025 | Option exercise | +10,091 | $5.04 | $50.86K | 902,583 |
| Charles K. Gayer President and CCO | Dec 22, 2025 | Option exercise | +14,142 | $3.22 | $45.54K | 892,492 |
| Charles K. Gayer President and CCO | Dec 22, 2025 | Option exercise | +50,000 | $5.51 | $275.50K | 952,583 |
| Alane P. Barnes Chief Legal Officer | Dec 19, 2025 | Tax withholding | −16,902 | $7.41 | $125.24K | 420,524 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 19, 2025 | Tax withholding | −61,793 | $7.41 | $457.89K | 1,323,429 |
| Charles K. Gayer President and CCO | Dec 19, 2025 | Tax withholding | −11,477 | $7.41 | $85.04K | 878,350 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 18, 2025 | Gift | +10,000 | – | – | 40,000 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 18, 2025 | Gift | +10,000 | – | – | 40,000 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 18, 2025 | Gift | −20,000 | – | – | 1,385,222 |
| Charles K. Gayer President and CCO | Dec 17, 2025 | Award | +471,000 | – | – | 889,827 |
| Alane P. Barnes Chief Legal Officer | Dec 17, 2025 | Award | +121,700 | – | – | 437,426 |
| Babar Ghias Chief Financial Officer | Dec 17, 2025 | Award | +121,700 | – | – | 268,700 |
| Alane P. Barnes Chief Legal Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −21,210 | $7.65 | $162.26K | 315,726 |
| Charles K. Gayer President and CCO | Dec 12, 2025 | Tax withholding | −8,181 | $7.57 | $61.93K | 418,827 |
| Alane P. Barnes Chief Legal Officer | Dec 12, 2025 | Tax withholding | −8,540 | $7.57 | $64.65K | 336,936 |
| Jon P. Stonehouse Chief Executive Officer, Director | Dec 12, 2025 | Tax withholding | −27,368 | $7.57 | $207.18K | 1,405,222 |
| Alane P. Barnes Chief Legal Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −19,770 | $7.65 | $151.24K | 345,476 |
| Alane P. Barnes Chief Legal Officer | Dec 2, 2025 | Sale(10b5-1 plan) | −50,906 | $7.21 | $367.03K | 365,246 |
| Alane P. Barnes Chief Legal Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −91,004 | $7.10 | $646.13K | 416,152 |
| Alane P. Barnes Chief Legal Officer | Dec 1, 2025 | Option exercise | +91,004 | $3.22 | $293.03K | 507,156 |
| Steven Frank Director | Nov 28, 2025 | Award | +1,566 | $7.18 | $11.24K | 17,618 |
| Vincent Milano Director | Nov 28, 2025 | Award | +783 | $7.18 | $5.62K | 91,219 |
| Amy E. McKee Director | Nov 28, 2025 | Award | +783 | $7.18 | $5.62K | 41,790 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioCryst Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 50,200 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Amy E. McKee Director | May 18, 2026 | 11,180 | $99.91K | May 18, 2026 | Stock Plan Activity |
| Alane P. Barnes Officer | May 13, 2026 | 62,500 | $596.25K | May 13, 2026 | Option Granted - 12/20/2017 |
| Theresa Heggie Director | Mar 20, 2026 | 49,933 | $504.62K | Mar 20, 2026 | Option Granted 06/12/2024 |
| Alane P. Barnes Officer | Mar 16, 2026 | 150,000 | $1.37M | Mar 16, 2026 | Option Granted - 02/27/2017 |
| Jon P. Stonehouse Director | Mar 2, 2026 | 305,995 | $2.65M | Mar 2, 2026 | Option Granted - 05/23/2016 |
| Alane P. Barnes Officer | Dec 22, 2025 | 21,773 | $166.56K | Dec 22, 2025 | Restricted Stock Vesting |
| Alane P. Barnes Officer | Dec 15, 2025 | 21,210 | $162.26K | Dec 15, 2025 | Restricted Stock Vesting |
| Alane P. Barnes Officer | Dec 3, 2025 | 19,770 | $151.24K | Dec 3, 2025 | Restricted Stock Vesting |
| Alane P. Barnes Officer | Dec 2, 2025 | 50,906 | $367.22K | Dec 2, 2025 | ESPP Purchase |
| Alane P. Barnes Officer | Dec 1, 2025 | 91,004 | $644.31K | Dec 1, 2025 | Option Granted - 05/23/2016 |
| Helen M. Thackray Officer | Nov 25, 2025 | 48,229 | $327.96K | Nov 25, 2025 | Stock plan activity |
| Helen M. Thackray Officer | Nov 21, 2025 | 43,275 | $307.69K | Nov 21, 2025 | Stock Plan Activity |
| Machelle Sanders Officer | Nov 13, 2025 | 9,600 | $68.54K | Nov 13, 2025 | Restricted Stock Vesting |
| Theresa Heggie Director | Aug 13, 2025 | 70,000 | $595.87K | Aug 13, 2025 | Option Granted - 05/29/2019 |
| Nancy J. Hutson Director | Dec 13, 2024 | 7,000 | $52.58K | Dec 13, 2024 | RSU Vesting under Stock Plan |
Congress trades
5 trades in BioCryst Pharmaceuticals reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Jul 10, 2026 | $1K–15K | Sep 4, 2026 56 days late |
| Gilbert Cisneros CA31 | Bought | Nov 13, 2025 | $1K–15K | Dec 15, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Oct 16, 2023 | $1K–15K | Nov 11, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold | Sep 15, 2023 | $1K–15K | Oct 15, 2023 |
| Josh Gottheimer NJ05 · joint account | Bought | Aug 11, 2022 | $1K–15K | Sep 16, 2022 |
See a number that looks wrong?